DK2959894T1 - S1p-receptormodulatorer til behandling af multipel sklerose - Google Patents

S1p-receptormodulatorer til behandling af multipel sklerose Download PDF

Info

Publication number
DK2959894T1
DK2959894T1 DK15177166.4T DK15177166T DK2959894T1 DK 2959894 T1 DK2959894 T1 DK 2959894T1 DK 15177166 T DK15177166 T DK 15177166T DK 2959894 T1 DK2959894 T1 DK 2959894T1
Authority
DK
Denmark
Prior art keywords
treatment
multiple sclerosis
receptor modulators
modulators
receptor
Prior art date
Application number
DK15177166.4T
Other languages
English (en)
Other versions
DK2959894T3 (da
Inventor
Peter C Hiestand
Christian Schnell
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36888144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2959894(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of DK2959894T1 publication Critical patent/DK2959894T1/da
Application granted granted Critical
Publication of DK2959894T3 publication Critical patent/DK2959894T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK15177166.4T 2006-06-27 2007-06-25 S1p-receptormodulatorer til behandling af multipel sklerose DK2959894T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612721.1A GB0612721D0 (en) 2006-06-27 2006-06-27 Organic compounds
EP13186359.9A EP2698154A1 (en) 2006-06-27 2007-06-25 S1P receptor modulators for treating multiple sclerosis

Publications (2)

Publication Number Publication Date
DK2959894T1 true DK2959894T1 (da) 2021-12-20
DK2959894T3 DK2959894T3 (da) 2022-10-17

Family

ID=36888144

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15177166.4T DK2959894T3 (da) 2006-06-27 2007-06-25 S1p-receptormodulatorer til behandling af multipel sklerose

Country Status (20)

Country Link
US (3) US20100168078A1 (da)
EP (4) EP2959894B1 (da)
JP (8) JP2009541386A (da)
KR (6) KR20090024281A (da)
CN (2) CN101478961B (da)
AU (7) AU2007264031C1 (da)
BR (1) BRPI0713985A2 (da)
CA (1) CA2653569C (da)
DE (1) DE15177166T1 (da)
DK (1) DK2959894T3 (da)
ES (1) ES2887042T3 (da)
GB (1) GB0612721D0 (da)
HU (1) HUE059922T4 (da)
LT (1) LT2959894T (da)
MX (3) MX2008016133A (da)
PL (1) PL2959894T3 (da)
PT (1) PT2959894T (da)
RU (1) RU2617502C2 (da)
SI (1) SI2959894T1 (da)
WO (1) WO2008000419A1 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
CA2684953C (en) * 2007-05-04 2016-08-09 Novartis Ag Use of s1p receptor modulator
JP2011525189A (ja) * 2008-06-20 2011-09-15 ノバルティス アーゲー 多発性硬化症を治療するための小児科の組成物
KR101618906B1 (ko) * 2008-08-18 2016-05-09 노파르티스 아게 말초 신경병증의 치료를 위한 화합물
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
KR20110101159A (ko) * 2008-12-18 2011-09-15 노파르티스 아게 신규 염
JP2012512884A (ja) 2008-12-18 2012-06-07 ノバルティス アーゲー １−（４−｛１−［（ｅ）−４−シクロヘキシル−３−トリフルオロメチル−ベンジルオキシイミノ］−エチル｝−２−エチル−ベンジル）−アゼチジン−３−カルボン酸の新規の多形相
US20120115840A1 (en) * 2008-12-18 2012-05-10 Lech Ciszewski Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
MX2012006028A (es) * 2009-11-24 2012-06-19 Allergan Inc Compuestos novedosos como moduladores de receptor con utilidad terapeutica.
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
JP6111202B2 (ja) 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
CN102120720B (zh) * 2011-01-25 2013-05-22 上海华升生物科技有限公司 盐酸芬戈莫德的合成新方法
BR112014009141A8 (pt) * 2011-10-21 2017-06-20 Novartis Ag regime de dosagem para um modulador ou agonista do receptor s1p
CN104170419B (zh) * 2012-03-23 2018-11-02 日本电气株式会社 订户服务器、监视服务器、移动终端、与之相关的方法和计算机可读介质
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
CN105611917A (zh) 2013-10-11 2016-05-25 帝国制药美国公司 局部鞘氨醇-1-磷酸酯受体激动剂制剂及其使用方法
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US20190047951A1 (en) 2016-01-04 2019-02-14 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
JP7749552B2 (ja) 2019-10-31 2025-10-06 イドルシア・ファーマシューティカルズ・リミテッド Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤
AU2022328858A1 (en) * 2021-08-20 2024-02-22 The Brain Protection Company PTY LTD Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB612721A (en) 1946-02-11 1948-11-17 Richard William Bailey Improvements in combustion product power plant
DE69321823T2 (de) 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-amino-1, 3- propandiolverbindung und immunosuppressium
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ES2240868T3 (es) 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
DK1140173T4 (da) 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
CN1660840A (zh) 1999-03-30 2005-08-31 诺瓦提斯公司 治疗炎性疾病的酞嗪衍生物
AR025068A1 (es) 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
PT1254138E (pt) 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
DE10033541C2 (de) 2000-07-11 2003-05-15 Litef Gmbh Lichtleitfaserspule für ein faseroptisches Sagnac-Interferometer und Verfahren zu ihrer Herstellung
CN1328387C (zh) 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
RU2199339C2 (ru) 2001-02-23 2003-02-27 Общество с ограниченной ответственностью "Биотех" Способ лечения рассеянного склероза
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
JP4430941B2 (ja) 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
PT1505959E (pt) * 2002-05-16 2009-02-05 Novartis Ag Utilização de agentes de ligação do receptor edg em cancro
BR0311347A (pt) * 2002-05-27 2005-02-22 Novartis Ag Alcanóis bis-aromáticos
EP1575576A2 (en) 2002-09-24 2005-09-21 Novartis AG Organic compounds
KR20040048231A (ko) * 2002-12-02 2004-06-07 주식회사 두산 신생혈관생성 억제제 및 그를 포함한 암 치료용 키트
FR2848495B1 (fr) * 2002-12-12 2006-11-17 Sidel Sa Four pour chauffer au defile des ebauches de recipients en materiau thermoplastique
PE20130200A1 (es) 2003-04-08 2013-03-09 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
CL2004001120A1 (es) 2003-05-19 2005-04-15 Irm Llc Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
EP1644367B1 (en) * 2003-05-19 2015-10-14 Novartis AG Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
CA2567686A1 (en) * 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
CN101102791B (zh) * 2004-11-18 2011-12-14 英克隆有限责任公司 抗血管内皮生长因子受体-1的抗体
KR20070085465A (ko) * 2004-11-29 2007-08-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
US20060134111A1 (en) * 2004-12-17 2006-06-22 Genentech, Inc. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
RU2278687C1 (ru) 2005-06-16 2006-06-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" (ГОУ ВПО БГМУ РОСЗДРАВА РОССИИ) Способ лечения ремиттирующего рассеянного склероза
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP2323679A4 (en) 2008-07-25 2012-08-22 Univ Colorado CLIP INHIBITORS AND METHODS FOR MODULATING IMMUNE FUNCTION
GB2527550B (en) 2014-06-25 2016-09-21 Cook Medical Technologies Llc Implantable medical device with lumen constriction

Also Published As

Publication number Publication date
AU2007264031C1 (en) 2016-12-15
AU2011201844B2 (en) 2012-10-25
AU2013200356A1 (en) 2013-02-14
AU2011201844A1 (en) 2011-05-19
JP2025016462A (ja) 2025-02-04
AU2013200356B2 (en) 2016-09-29
ES2887042T3 (es) 2022-11-14
JP2009541386A (ja) 2009-11-26
HUE059922T2 (hu) 2023-01-28
AU2018202210A1 (en) 2018-04-26
CN101478961A (zh) 2009-07-08
US9187405B2 (en) 2015-11-17
WO2008000419A1 (en) 2008-01-03
EP2959894A1 (en) 2015-12-30
US20110237682A1 (en) 2011-09-29
KR20140069178A (ko) 2014-06-09
CN103550195A (zh) 2014-02-05
RU2013131176A (ru) 2015-01-20
MX2022008950A (es) 2022-08-11
KR20170138583A (ko) 2017-12-15
EP2037906A1 (en) 2009-03-25
JP2013166761A (ja) 2013-08-29
RU2569732C2 (ru) 2015-11-27
AU2016266058A1 (en) 2016-12-22
MX2008016133A (es) 2009-01-15
KR20150122812A (ko) 2015-11-02
PL2959894T3 (pl) 2022-11-14
KR20190030776A (ko) 2019-03-22
PL15177166T1 (pl) 2022-03-07
JP2019167352A (ja) 2019-10-03
KR20090024281A (ko) 2009-03-06
CA2653569A1 (en) 2008-01-03
RU2009102278A (ru) 2010-08-10
DK2959894T3 (da) 2022-10-17
EP2959894B1 (en) 2022-10-12
EP3797765A1 (en) 2021-03-31
HK1214758A1 (en) 2016-08-05
US20100168078A1 (en) 2010-07-01
HUE15177166T1 (hu) 2022-05-28
JP2023098949A (ja) 2023-07-11
CA2653569C (en) 2016-06-21
LT2959894T (lt) 2022-11-10
PT2959894T (pt) 2022-10-18
HUE059922T4 (hu) 2024-05-28
AU2007264031B2 (en) 2011-01-27
AU2019219818A1 (en) 2019-09-12
JP6931019B2 (ja) 2021-09-01
BRPI0713985A2 (pt) 2012-11-20
US20140228446A1 (en) 2014-08-14
JP7258832B2 (ja) 2023-04-17
GB0612721D0 (en) 2006-08-09
JP2021035955A (ja) 2021-03-04
MX2019012750A (es) 2020-02-03
KR20210010956A (ko) 2021-01-28
AU2021202395A1 (en) 2021-05-20
RU2617502C2 (ru) 2017-04-25
AU2007264031A1 (en) 2008-01-03
JP2016185957A (ja) 2016-10-27
US8741963B2 (en) 2014-06-03
ES2887042T1 (es) 2021-12-21
DE15177166T1 (de) 2022-01-27
CN101478961B (zh) 2013-11-27
SI2959894T1 (sl) 2022-11-30
JP2018109018A (ja) 2018-07-12
EP2698154A1 (en) 2014-02-19

Similar Documents

Publication Publication Date Title
DK2959894T1 (da) S1p-receptormodulatorer til behandling af multipel sklerose
CY2020014I1 (el) Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p
DK2307042T3 (da) Modulering af trpv: vps10p-domænereceptorsystem til behandlingen af smerte
DK2038290T3 (da) Modulatorer af toll-lignende receptor 7
DK2500047T3 (da) Lægemiddelfrigivende coatinger til medicinske indretninger
DK2431359T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
BRPI0813653A2 (pt) Compostos de imidazotiazol moduladores de sirtuína
DK2034830T3 (da) Anti-vla-1-antistof til behandling af slagtilfælde
HUE051206T2 (hu) Módszerek progresszív szklerózis multiplex kezelésére
BRPI0813651A2 (pt) Compostos de tiazolopiridina moduladores de sirtuína
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2117523T3 (da) Inhibitorer af AKT-aktivitet
DK2086642T3 (da) Dnase til behandling af subfertilitet hos mænd
PT2487166T (pt) Moduladores de propriedades farmacocinéticas de agentes terapêuticos
DK2240130T3 (da) Indretning til behandling af fedme
DK1979314T3 (da) Indolsulfonamidmodulatorer af progesteronreceptorer
DK2021330T3 (da) Benzimidazolmodulatorer af VR1
DK2117525T3 (da) Anvendelse af 1-phenyl-3-dimethylamino-propanforbindelser til behandling af neuropatismerte
DK3300743T3 (da) Fremgangsmåder til indgivelse af vaccine
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
DK1986622T3 (da) Små-molekyle-modulatorer af Trp-p8-aktivitet
DK2079843T3 (da) Fremgangsmåde til fremstilling af biogas
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK2099446T3 (da) Fremgangsmåde til behandling af inflammatorisk tarmsygdom
DK2104464T3 (da) Fremgangsmåde til rekonstruktion af tænder